• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Pro, B
    Advani, R
    Brice, P
    Bartlett, N
    Rosenblatt, J
    Illidge, Timothy M
    Matous, J
    Ramchandren, R
    Fanale, M
    Connors, J
    Fenton, K
    Huebner, D
    Pinelli, J
    Kennedy, D
    Shustov, A
    Show allShow less
    Affiliation
    Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, United States
    Issue Date
    2017-10-03
    
    Metadata
    Show full item record
    Abstract
    This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of patients treated on this trial. Among all enrolled patients (N=58), no progressions were observed beyond 40 months, and median OS was not reached. Patients with a complete response (CR), as assessed by the investigator (38 of 58, 66%), continued to demonstrate improved outcomes with neither median OS nor PFS reached. Of the 38 CR patients, 16 received a consolidative stem cell transplant (SCT) with median PFS not reached. Among patients who were on-study and in-remission at study closure, 16 patients had not received any new treatment after single-agent brentuximab vedotin other than consolidative SCT. Among this subset of 16, 8 patients received SCT, and the remaining 8 patients (14% of all enrolled patients) remained in sustained remission without consolidative SCT or any new anticancer therapy. Thirty-three patients experienced peripheral neuropathy, among whom, the majority (30 of 33, 91%) had experienced resolution or improvement at their last assessment. These final results, demonstrating a high rate of peripheral neuropathy resolution, and durable remissions in a subset of patients with relapsed or refractory systemic ALCL, provide evidence that single-agent brentuximab vedotin may be a potentially curative treatment option. This trial was registered at www.clinicaltrials.gov as #NCT00866047.
    Citation
    Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. 2017, Blood
    Journal
    Blood
    URI
    http://hdl.handle.net/10541/620690
    DOI
    10.1182/blood-2017-05-780049
    PubMed ID
    28974506
    Type
    Article
    Language
    en
    Description
    Lymphoma Research Team
    ISSN
    1528-0020
    ae974a485f413a2113503eed53cd6c53
    10.1182/blood-2017-05-780049
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    • Authors: O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J
    • Issue date: 2018 Feb
    • Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
    • Authors: Chihara D, Wong S, Feldman T, Fanale MA, Sanchez L, Connors JM, Savage KJ, Oki Y
    • Issue date: 2019 Feb
    • Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
    • Authors: Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A
    • Issue date: 2016 Sep 22
    • Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
    • Authors: Illidge T, Bouabdallah R, Chen R, Gopal AK, Moskowitz CH, Ramchandren R, Shustov AR, Tilly H, Trippett TM, Gibb A, Grove LE, Advani R
    • Issue date: 2015 Mar
    • Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
    • Authors: Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A
    • Issue date: 2014 Mar 19
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.